TrialInvestigational new drugs2017

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.

Khaldoun Almhanna et al.PubMed ↗Publisher ↗

No numbers read from the abstract.